Total medical devices industry cross border deals worth $2.89bn were announced globally for March 2021, with the $1.07bn asset transaction with Lumenis being the sector’s biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 381.8% over the previous month of $599.82m and a rise of 2.5% when compared with the last 12-month average of $2.82bn.
In terms of number of cross border deals, the sector saw a rise of 25.64% with 49 deals in March 2021 when compared to the last 12-month average of 39 deals.
In value terms, Middle East and Africa led the activity with cross border deals worth $1.21bn in March 2021.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataMedical Devices industry cross border deals in March 2021: Top deals
The top five cross border deals accounted for 60.9% of the overall value during March 2021.
The combined value of the top five cross border deals stood at $1.76bn, against the overall value of $2.89bn recorded for the month.
The top five medical devices industry cross border deals of March 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction with Lumenis
2) The $240m acquisition of Alydia Health by Organon &
3) L Catterton Partners’ $181.4m private equity deal with PHC
4) The $159m acquisition deal of Diagenode by Hologic
5) SeaSpine’s acquisition deal with 7D Surgical for $110m.